MT 100 was developed as an oral, first-line treatment for migraine. It is a patented sequential release tablet containing two approved drugs, naproxen sodium, which relieves pain and reduces inflammation, and metoclopramide, which accelerates the absorption of naproxen and contributes to the relief of migraine.
“The authorization for MT 100 by the MHRA is a milestone event for Pozen as it’s our first regulatory approval for one of our drug candidates. We are currently seeking a partner who can bring MT 100 to market in the UK and eventually in other countries outside the US,” stated Dr John Plachetka, chairman, president and CEO of Pozen.
Since its inception, Pozen has focused its efforts primarily on the development of products for the treatment of migraine, although the company is also exploring the development of product candidates in other acute and chronic pain and pain-related therapeutic areas.